StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report sent to investors on Wednesday morning. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright decreased their price target on DBV Technologies from $10.00 to $5.00 and set a buy rating for the company in a report on Wednesday, May 8th.

DBV Technologies Price Performance

DBVT opened at $0.61 on Wednesday. DBV Technologies has a 52-week low of $0.42 and a 52-week high of $2.26. The company has a 50 day moving average of $0.69 and a two-hundred day moving average of $0.80. The company has a market cap of $117.57 million, a P/E ratio of -1.45 and a beta of 0.73.

Shares of DBV Technologies are going to reverse split on Monday, June 3rd. The 1-2 reverse split was announced on Monday, June 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 3rd.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.08. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. The company had revenue of $1.41 million for the quarter, compared to analyst estimates of $3.20 million. Research analysts anticipate that DBV Technologies will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On DBV Technologies

A number of hedge funds have recently bought and sold shares of DBVT. Yiheng Capital Management L.P. boosted its stake in shares of DBV Technologies by 6.2% during the 1st quarter. Yiheng Capital Management L.P. now owns 5,568,909 shares of the company’s stock valued at $4,172,000 after buying an additional 327,345 shares during the last quarter. Cowen AND Company LLC bought a new position in DBV Technologies during the 4th quarter valued at $49,000. Optiver Holding B.V. grew its holdings in DBV Technologies by 595.2% during the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after acquiring an additional 235,337 shares in the last quarter. Finally, Landscape Capital Management L.L.C. bought a new stake in shares of DBV Technologies in the 3rd quarter worth about $94,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.